453 related articles for article (PubMed ID: 18381624)
21. Cell-penetrating properties of the transactivator of transcription and polyarginine (R9) peptides, their conjugative effect on nanoparticles and the prospect of conjugation with arsenic trioxide.
Kanwar JR; Gibbons J; Verma AK; Kanwar RK
Anticancer Drugs; 2012 Jun; 23(5):471-82. PubMed ID: 22241171
[TBL] [Abstract][Full Text] [Related]
22. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier.
Liu L; Venkatraman SS; Yang YY; Guo K; Lu J; He B; Moochhala S; Kan L
Biopolymers; 2008; 90(5):617-23. PubMed ID: 18412128
[TBL] [Abstract][Full Text] [Related]
23. Cell-targeting and cell-penetrating peptides for delivery of therapeutic and imaging agents.
Juliano RL; Alam R; Dixit V; Kang HM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2009; 1(3):324-35. PubMed ID: 20049800
[TBL] [Abstract][Full Text] [Related]
24. Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state-of-the-art.
Moutinho CG; Matos CM; Teixeira JA; Balcão VM
J Drug Target; 2012 Feb; 20(2):114-41. PubMed ID: 22023555
[TBL] [Abstract][Full Text] [Related]
25. Simplified preparation via streptavidin of antisense oligomers/carriers nanoparticles showing improved cellular delivery in culture.
Wang Y; Nakamura K; Liu X; Kitamura N; Kubo A; Hnatowich DJ
Bioconjug Chem; 2007; 18(4):1338-43. PubMed ID: 17605463
[TBL] [Abstract][Full Text] [Related]
26. Properties of cell penetrating peptides (CPPs).
Kerkis A; Hayashi MA; Yamane T; Kerkis I
IUBMB Life; 2006 Jan; 58(1):7-13. PubMed ID: 16540427
[TBL] [Abstract][Full Text] [Related]
27. Active targeting of brain tumors using nanocarriers.
Béduneau A; Saulnier P; Benoit JP
Biomaterials; 2007 Nov; 28(33):4947-67. PubMed ID: 17716726
[TBL] [Abstract][Full Text] [Related]
28. Cell culture and xenograft-bearing animal studies of radiolabeled antisense DNA carrier nanoparticles with streptavidin as a linker.
Nakamura K; Wang Y; Liu X; Kubo A; Hnatowich DJ
J Nucl Med; 2007 Nov; 48(11):1845-52. PubMed ID: 17978353
[TBL] [Abstract][Full Text] [Related]
29. Strategies for cytosolic delivery of liposomal macromolecules.
Fretz MM; Mastrobattista E; Koning GA; Jiskoot W; Storm G
Int J Pharm; 2005 Jul; 298(2):305-9. PubMed ID: 15941633
[TBL] [Abstract][Full Text] [Related]
30. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier.
Liu L; Guo K; Lu J; Venkatraman SS; Luo D; Ng KC; Ling EA; Moochhala S; Yang YY
Biomaterials; 2008 Apr; 29(10):1509-17. PubMed ID: 18155137
[TBL] [Abstract][Full Text] [Related]
31. Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements.
Koren E; Apte A; Sawant RR; Grunwald J; Torchilin VP
Drug Deliv; 2011 Jul; 18(5):377-84. PubMed ID: 21438724
[TBL] [Abstract][Full Text] [Related]
32. Cell-penetrating peptides as delivery vehicles for biology and medicine.
Stewart KM; Horton KL; Kelley SO
Org Biomol Chem; 2008 Jul; 6(13):2242-55. PubMed ID: 18563254
[TBL] [Abstract][Full Text] [Related]
33. Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications.
Kamide K; Nakakubo H; Uno S; Fukamizu A
Int J Mol Med; 2010 Jan; 25(1):41-51. PubMed ID: 19956900
[TBL] [Abstract][Full Text] [Related]
34. Comparison of four different peptides to enhance accumulation of liposomes into the brain.
Qin Y; Zhang Q; Chen H; Yuan W; Kuai R; Xie F; Zhang L; Wang X; Zhang Z; Liu J; He Q
J Drug Target; 2012 Apr; 20(3):235-45. PubMed ID: 22188312
[TBL] [Abstract][Full Text] [Related]
35. Nanocarriers for oral drug delivery.
Zhang L; Wang S; Zhang M; Sun J
J Drug Target; 2013 Jul; 21(6):515-27. PubMed ID: 23621127
[TBL] [Abstract][Full Text] [Related]
36. Intracellular Delivery of Molecular Cargo Using Cell-Penetrating Peptides and the Combination Strategies.
Li H; Tsui TY; Ma W
Int J Mol Sci; 2015 Aug; 16(8):19518-36. PubMed ID: 26295227
[TBL] [Abstract][Full Text] [Related]
37. The augmentation of intracellular delivery of peptide therapeutics by artificial protein transduction domains.
Yoshikawa T; Sugita T; Mukai Y; Abe Y; Nakagawa S; Kamada H; Tsunoda S; Tsutsumi Y
Biomaterials; 2009 Jul; 30(19):3318-23. PubMed ID: 19304319
[TBL] [Abstract][Full Text] [Related]
38. Cell-penetrating-peptide-coated nanoribbons for intracellular nanocarriers.
Lim YB; Lee E; Lee M
Angew Chem Int Ed Engl; 2007; 46(19):3475-8. PubMed ID: 17385811
[No Abstract] [Full Text] [Related]
39. TAT-peptide modified liposomes: preparation, characterization, and cellular interaction.
Fretz MM; Storm G
Methods Mol Biol; 2010; 605():349-59. PubMed ID: 20072893
[TBL] [Abstract][Full Text] [Related]
40. Generation of carrier peptides for the delivery of nucleic acid drugs in primary cells.
Rennert R; Neundorf I; Jahnke HG; Suchowerskyj P; Dournaud P; Robitzki A; Beck-Sickinger AG
ChemMedChem; 2008 Feb; 3(2):241-53. PubMed ID: 18205166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
